⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
STEP 1 trial: double-blind RCT, N=1961 adults (BMI ≥30 or ≥27 + comorbidity, without diabetes), randomized 2:1 to semaglutide 2.4mg/week vs placebo plus lifestyle intervention, 68 weeks. Mean weight change: −14.9% vs −2.4% (diff −12.4pp; 95% CI −13.4 to −11.5; P<0.001). Weight reduction ≥5%: 86.4% vs 31.5% (P<0.001). Funded by Novo Nordisk.
Coeff. authors = avg(0.85, 0.70) = 0.77
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.77, 0.95) = 0.77← lowest dominates
Final coefficient : 0.77
Final score = 45.4/52.8 × 0.77 × 100 = 66/100
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM — 2023 · The New England Journal of Medicine
Contrasted resultsA randomized trial of sugar-sweetened beverages and adolescent body weight.
Ebbeling CB — 2012 · New England Journal of Medicine
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
Dai H — 2025 · JAMA Oncology
Calorie Restriction with or without Time-Restricted Eating in Weight Loss.
Liu D — 2022 · New England Journal of Medicine
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP — 2016 · The New England Journal of Medicine